Roche: positive results for trial on faricimab
(CercleFinance.com) - Roche has announced positive results of the STAIRWAY phase II study, which examined the prolonged effect of faricimab (RG7716) in (wet) age-related macular degeneration (AMD), a major cause of blindness in people aged 60 and over.
"At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vision outcomes comparable to ranibizumab dosed every four weeks," said the Swiss pharmaceutical group.
The group announced the study's results at the 2018 meeting of the American Academy of Ophthalmology in Chicago, as well as data on the Port Delivery System with ranibizumab in patients with neovascular DMLA.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
"At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vision outcomes comparable to ranibizumab dosed every four weeks," said the Swiss pharmaceutical group.
The group announced the study's results at the 2018 meeting of the American Academy of Ophthalmology in Chicago, as well as data on the Port Delivery System with ranibizumab in patients with neovascular DMLA.
Copyright (c) 2018 CercleFinance.com. All rights reserved.